ClinicalTrials.gg
CompletedNCT05153343Updated Oct 1, 2025

Safety of Flonoltinib Maleate Tablets for the Treatment of Patients With Myeloproliferative

A Phase 1/2 interventional study of flonoltinib 25mg and flonoltinib 100mg in Myeloproliferative Neoplasm (MPN) and Myelofibrosis,MF, sponsored by Chengdu Zenitar Biomedical Technology Co., Ltd. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-01.

Sponsored by Chengdu Zenitar Biomedical Technology Co., Ltd · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
31
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies in Myeloproliferative Disorders with a site in China — 5 open to participants now, 9 under way, 4 of them phase 3. Myeloproliferative Disorders · China.

Enrollment
11th of 15
31 · median 160
Started
2021
with 5 others
Phase 1/2
2 of 19
none open now
Registered
15th of 19
by date
Lead sponsor
1 of 19
Chengdu Zenitar Biomedical Technology Co., Ltd

Among the 19 studies in Myeloproliferative Disorders with a site in China, this one is the 11th largest by enrollment of the 15 interventional ones that give a count, is one of 6 that started in 2021, is one of 2 in phase 1/2, and was the 15th registered.

Myeloproliferative Disorders

668 studies on the registry are indexed under Myeloproliferative Disorders; 111 are open to participants now.

Browse Myeloproliferative Disorders studies →

Open to participants now

5 of the 19 studies in Myeloproliferative Disorders with a site in China are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 88 Myeloproliferative Disorders studies recruiting now, 64 (73%) set no upper age limit and 18 (20%) stop at 75 or younger; 22 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Myeloproliferative Disorders with a site in China, or all of them as a file.
02

Study summary

Flonoltinib Maleate (FM) targets Janus kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3). FM is a dual target inhibitor of JAK2/FLT3.FM has the activity of inhibiting JAK2 signaling pathway, and pharmacodynamics evaluation also confirmed that FM has a good therapeutic effect on the primary splenomegaly model of mice induced by JAK2V617 mutation.Therefore, FM has the potential to treat bone marrow proliferative tumors.The drug is intended to be used in patients with MPN, mainly including medium-risk or high-risk myelofibrosis (FM) (including primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PostPV-MF) and post-primary thrombocythemia myelofibrosis (postET-MF)), Polycythemia vera (PV) and essential thrombocythemia (ET) were the primary causes of thrombocythemia and thrombocythemia.

FM has high inhibitory activity against JAK family and FLT3 kinase, suggesting that FM may have a certain therapeutic effect on AML disease.

In vitro experiments on the proliferation of JAK2-dependent and Flt3-related tumor cell lines with FM showed that the tumor cell lines had a significant inhibitory effect. The IC50 of half of the tumor cell lines was less than 0.5 μm, which was better than or equal to the similar drugs Ruxolitinib and Fedratinib.

The effect of FM on tumor cells from MPN patients indicated that FM has the potential to treat MPN disease.

In multiple animal models of bone marrow proliferative tumors with JAK2V617F mutations, FM showed superior efficacy and low toxicity (no obvious VISCAL toxicity) than existing drugs on the market, and the tumor inhibition effect of FM showed a good dose-dependent relationship.

Objectives of Study

Main Purpose:

  1. Tolerance and safety of flonoltinib maleate Tablets tablets in patients with bone marrow proliferative tumors;
  2. To observe the possible dose-limiting toxicity(DLT) of flonoltinib maleate tablets in patients with bone marrow proliferative tumors,To determine the maximum tolerated dose(MTD) of flonoltinib maleate tablets,To provide the basis for the recommended dose and design scheme of the later clinical trial.

Secondary Purpose:

  1. To evaluate the pharmacokinetic characteristics of single and repeated oral administration of flonoltinib maleate tablets in patients with bone marrow proliferative tumors;
  2. To evaluate the primary efficacy of single and multiple oral flonoltinib maleate tablets in patients with bone marrow proliferative tumors.
03

Conditions studied

  • Myeloproliferative Neoplasm (MPN)
  • Myelofibrosis,MF
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18, gender unlimited;
  2. Patients diagnosed as PMF, PV (PV at least 24 weeks), ET according to WHO criteria (2016 edition), or post-PV-MF or post-ET-MF according to IWG-MRT criteria;
  3. Any of the following criteria is met :(1) Patients receiving treatment for myeloid fibrosis must be at least medium-risk -1 or high risk as assessed according to the DIPSS risk grouping criteria; (2) PV and ET patients who are resistant or intolerant to hydroxyurea and/or interferon therapy;
  4. No immediate plans for a stem cell transplant;
  5. At least 4 weeks or more than 5 half-lives (whichever is longer) after receiving the last antitumor therapy (chemotherapy, radiotherapy, biotherapy or immunotherapy) before enrollment;
  6. Expected survival ≥12 weeks;
  7. ≤2;
  8. Splenomegaly: palpate the margin of the spleen (the farthest point of the spleen) at least 5 cm below the costal margin; Or not accessible due to body type (obesity), but confirmed by MRI (CT scan if necessary) spleen assessment at screening time, the volume is ≥450 cm3;
  9. Bone marrow primitive cells and peripheral blood primitive cells ≤10%;
  10. ≥75×109 /L, ≥1.0×109 /μL, HGB> without the assistance of colony stimulating factor, growth factor, thrombogenic factor or platelet infusion; 80 g/L. Subjects did not receive growth factor, colony-stimulating factor, thrombogenic factor or platelet transfusions within 2 weeks before examination.
  11. Heart, lung, liver, kidney, pancreas without serious organic lesions ( (left ventricular ejection fraction) ≥45%; Total ≤1.5×; Serum creatinine ≤1.5×ULN or CCR> 40 ml/min. (ALT) ≤2×ULN; Aspartate aminotransferase (AST) ≤2×ULN;
  12. No severe coagulation abnormalities (PT≤1.5×ULN, ≤1.5×ULN, TT≤1.5×ULN);
  13. Those who agree to participate in the study and sign the ;
  14. Agree to comply with the regulations of the hospital and research institution.

Exclusion criteria

Exclusion Criteria:

  1. The toxicity of previous anticancer therapy does not recover to grade I or below (except for hair loss), or does not fully recover from previous surgery (major surgery within 4 weeks);
  2. Allergic constitution, allergy to test drugs and their ;
  3. Any significant clinical or laboratory abnormalities that the investigator considers to affect the safety reviewer, such as: A. Uncontrolled diabetes - fasting glucose > 250 mg/dL (13.9 mmol/L), b. Patients with hypertension who cannot be reduced to the following range after treatment with two or less antihypertensive drugs (systolic blood pressure \< 160 mmHg, diastolic blood pressure \< 100 mmHg), c. Peripheral neuropathy (NCI-CTC AE V5.0 Grade 2 or above);
  4. Patients with a history of congestive heart failure, unstable angina pectoris or myocardial infarction, cerebrovascular accidents, or pulmonary embolism within the first 6 months were screened;
  5. Patients with impaired heart function ( measured by ultrasonic ; ST segment descending in two or more channels in 45% or complete left bundle branch block > 1 mm or T wave inverted; Congenital ventricular arrhythmia, tachycardia (>; 100 beats/min), bradycardia (lt; 50 times/min), ECG > 450 ms (male), QTc > 480 MS (female) or clinically significant heart disease (such as unstable angina pectoris, congestive heart failure, myocardial infarction within 6 months);
  6. Arrhythmic disease requiring treatment, or QTC interphase (QTCB) > 480 ms;
  7. Any active infections requiring treatment at the time of screening;
  8. Patients who had previously undergone splenectomy or who had received radiotherapy in the splenic region within 12 months prior to screening;
  9. Positive antibody, positive active virus (HBsAg positive, HBV-DNA positive or ≥1000 copies/mL), positive anti- antibody or HCV-RNA at screening time;
  10. Screening patients with epilepsy or using psychotropic drugs or sedatives;
  11. Pregnant or lactating women, fertile women/men who refuse to use during the trial and within 6 months after the trial;
  12. Patients who have had malignant tumors (except cured basal cell carcinoma of the skin and carcinoma in situ of the cervix) in the past 5 years;
  13. Concomitant with other serious diseases that the investigator believes may affect patient safety or compliance;
  14. Screening patients who participated in other new drugs or medical devices and took study drugs or used study devices within the previous 1 months;
  15. Within 2 weeks before randomization and into the group to use any drug for MF (JAK inhibitor, hydroxyurea), any immune modulators (such as Sally degree amine), any immune inhibitors, 10 mg/day or prednisone or equivalent strength of biological effect of , growth factors, such as EPO therapy, or within six drug half-life of patients;
  16. Intravenous use of either a potent or moderate inhibitor (such as ketoconazole, clarithromycin, itraconazole, nefazoldone, telimycin) or a potent CYP3A4 inducer (rifampicin perforatum) within two weeks prior to initial administration;
  17. Patients with a history of congenital or acquired bleeding diseases;
  18. Alcohol dependence or drug abuse;
  19. People who use grapefruit, star fruit or its products within 48 hours before taking the study drug for the first time, or who do not agree to prohibit the consumption of the above-mentioned food, drink or other special diet, which may affect the absorption, distribution, metabolism and excretion of the study drug;
  20. Other factors considered by the investigator to be unsuitable for participation in the study.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    Dose escalation group 1

    Flonoltinib 25mg

    Drug: flonoltinib 25mg

  • Experimental
    Dose escalation group 2

    Flonoltinib 50mg

    Drug: flonoltinib 50mg

  • Experimental
    Dose escalation group 3

    Flonoltinib 100mg

    Drug: flonoltinib 100mg

  • Experimental
    Dose escalation group 4

    Flonoltinib 150mg

    Drug: flonoltinib 150mg

  • Experimental
    Dose exploration stage group 5

    Flonoltinib 225mg

    Drug: flonoltinib 225mg

  • Experimental
    Extended Phase Dose Group

    Flonoltinib 100mg

    Drug: flonoltinib 100mg

Interventions

  • 1 case,The starting dose.Take the medicine once on Day1and Day 5-21,and then 14 days per cycle.

  • Take the medicine once on Day1and Day 5-21,and then 14 days per cycle.

  • Take the medicine once on Day1and Day 5-21,and then 14 days per cycle.

  • Take the medicine once on Day1and Day 5-21,and then 14 days per cycle.

  • Take the medicine once on Day1and Day 5-21,and then 14 days per cycle.

06

What researchers measure

Primary outcomes

  1. Flonoltinib Maleate Pharmacokinetics (PK):Cmax

    Estimation of maximum observed plasma concentration

    Time frame: 72hours

  2. Flonoltinib Maleate Pharmacokinetics (PK):Tmax

    Estimation of time to reach Cmax

    Time frame: 72hours

  3. Flonoltinib Maleate Pharmacokinetics (PK):AUC0-72h

    Estimation of AUC from time zero to the last measured time point

    Time frame: 72hours

  4. Flonoltinib Maleate Pharmacokinetics (PK):AUC0-∞

    Estimation of AUC from time zero extrapolated to infinity

    Time frame: 72hours

  5. Flonoltinib Maleate Pharmacokinetics (PK):MRT

    Estimation of mean residence time

    Time frame: 72hours

  6. Flonoltinib Maleate Pharmacokinetics (PK):Vd

    Estimation of apparent volume of distribution

    Time frame: 72hours

  7. Flonoltinib Maleate Pharmacokinetics (PK):t1/2

    Estimation of terminal elimination half-life

    Time frame: 72hours

  8. Flonoltinib Maleate Pharmacokinetics (PK):CLz/F

    Estimation of clearance when dosed orally

    Time frame: 72hours

  9. Flonoltinib Maleate Pharmacokinetics (PK):Vz/F

    Estimation of apparent volume of distribution when dosed orally

    Time frame: 72hours

  10. Flonoltinib Maleate Pharmacokinetics (PK):Ke

    Estimation of the elimination rate constant of a drug in the body

    Time frame: 72hours

07

Study locations

1 site
  • West China Hospital Sichuan University
    Chengdu, Sichuan 610000, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2021 to primary completion in Nov 2023, 23 months.

Of 23 phase 1/2 interventional studies under Myeloproliferative Disorders, half reached primary completion within 62 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 125. This study's 23 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2021
First posted
Dec 10, 2021
StartActual
Dec 27, 2021
Primary completionActual
Nov 29, 2023
CompletionActual
Mar 19, 2025
Last update
Oct 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05153343
Responsible party
Sponsor
First posted
Dec 10, 2021
Start date
Dec 27, 2021
Primary completion
Nov 29, 2023
Completion
Mar 19, 2025
Last update
Oct 1, 2025

Study contacts

ting Niu, doctor
principal investigator · West China Hospital
Yongsheng Wang, Doctor
principal investigator · West China Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Flonoltinib

Start the discussion